Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections.
The Liverpool epidemic strain (LES) of Pseudomonas aeruginosa is widespread among cystic fibrosis (CF) patients in the United Kingdom and has emerged recently in North America. In this study, we report the analysis of 24 "anomalous" CF isolates of P. aeruginosa that produced inconsistent results with regard to either pulsed-field gel electrophoresis (PFGE) or PCR tests for the LES. We used a new typing method, the ArrayTube genotyping system, to determine that of the 24 anomalous isolates tested, 13 were confirmed as the LES. LES isolates could not be clearly distinguished from non-LES isolates by two other commonly used genetic fingerprinting tests, randomly amplified polymorphic DNA (RAPD) analysis and BOX-PCR, and varied considerably in their carriage of LES genomic islands and prophages. The genomic instability of the LES suggests that identification of this emerging transmissible strain could be a challenging task, and it questions whether discrimination is always a desirable feature of bacterial typing methods in the context of chronic CF infections.
Fothergill
Joanne L
JL
Division of Medical Microbiology, University of Liverpool, Duncan Building, Daulby Street, Liverpool L69 3GA, United Kingdom.
White
Judith
J
Foweraker
Juliet E
JE
Walshaw
Martin J
MJ
Ledson
Martin J
MJ
Mahenthiralingam
Eshwar
E
Winstanley
Craig
C
D015373:Bacterial Typing Techniques; D003550:Cystic Fibrosis / Q000150:complications*; D016172:DNA Fingerprinting / Q000379:methods*; D016521:Electrophoresis, Gel, Pulsed-Field; D042822:Genomic Instability; D005838:Genotype; D006801:Humans; D017720:Molecular Epidemiology / Q000379:methods; D009656:North America; D011552:Pseudomonas Infections / Q000453:epidemiology / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000145:classification* / Q000235:genetics* / Q000302:isolation & purification; D019105:Random Amplified Polymorphic DNA Technique; D006113:United Kingdom
J Cyst Fibros. 2005 Sep;4(3):197-201
15967735
Infect Immun. 2001 Dec;69(12):7588-95
11705937
Microbiology (Reading). 2003 Apr;149(Pt 4):821-831
12686625
J Bacteriol. 2006 Nov;188(21):7426-39
16936024
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3100-5
18287045
Lancet. 2001 Aug 18;358(9281):558-60
11520530
J Clin Microbiol. 1995 Sep;33(9):2233-9
7494007
Appl Environ Microbiol. 2006 Mar;72(3):1900-9
16517637
Curr Microbiol. 1999 Jan;38(1):48-50
9841782
Mol Microbiol. 2006 Sep;61(6):1673-85
16968231
J Infect Dis. 2004 Feb 15;189(4):724-34
14767828
Pediatr Pulmonol. 2002 Aug;34(2):91-100
12112774
Thorax. 2004 Apr;59(4):334-6
15047956
BMC Microbiol. 2007 May 23;7:45
17521417
J Hosp Infect. 2005 Feb;59(2):102-7
15620443
Am J Respir Cell Mol Biol. 2005 Jul;33(1):56-64
15834046
J Cyst Fibros. 2008 May;7(3):258-61
18029234
J Clin Microbiol. 2000 Jan;38(1):464-5
10618146
Thorax. 2008 Sep;63(9):839-40
18728207
J Clin Microbiol. 2007 Aug;45(8):2590-8
17522270
J Antimicrob Chemother. 2005 Jun;55(6):921-7
15883175
J Clin Microbiol. 2007 Feb;45(2):386-91
17135440
Am J Respir Crit Care Med. 2002 Oct 1;166(7):988-93
12359659
Lancet. 1996 Sep 7;348(9028):639-42
8782753
J Bacteriol. 2004 Jul;186(13):4228-37
15205425
J Clin Microbiol. 1996 May;34(5):1129-35
8727889
J Med Microbiol. 2006 Jun;55(Pt 6):677-688
16687584
J Clin Microbiol. 2002 Dec;40(12):4607-11
12454160
Gene. 2006 May 10;372:199-207
16516407
Mol Diagn. 2003;7(3-4):195-200
15068391
Genome Res. 2009 Jan;19(1):12-23
19047519
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8101-6
17468398
Thorax. 2002 Jun;57(6):559-60
12037234
Thorax. 1998 May;53(5):432-6
9708241
J Med Microbiol. 2004 Jul;53(Pt 7):609-615
15184530
J Cyst Fibros. 2004 Mar;3(1):37-44
15463885
J Clin Microbiol. 2002 Sep;40(9):3300-7
12202570
Br Med Bull. 2002;61:81-96
11997300